Mineralys Therapeutics

Mineralys Therapeutics(MLYS)

RADNOR, PA
Biotechnology

Focus: Small Molecules

Mineralys Therapeutics is a life sciences company focused on Small Molecules.

CardiovascularNephrology
Funding Stage
PUBLIC
Open Jobs
14

Pipeline & Clinical Trials

Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
Chronic Kidney Disease
Phase 2
Clinical Trials (1)
NCT06150924Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
Phase 2
Phase 2
Clinical Trials (1)
NCT05769608A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
Phase 2
Phase 2
Clinical Trials (1)
NCT05001945Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
Phase 2
Phase 2
Clinical Trials (1)
NCT06785454A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
Phase 2
lorundrostat
Hypertension
Phase 3
Clinical Trials (1)
NCT05968430Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
Phase 3
Phase 3
Clinical Trials (1)
NCT06153693Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
Phase 3

Open Jobs (14)

Interview Prep Quick Facts
Portfolio: 6 clinical trials
Top TAs: Cardiovascular, Nephrology
SEC Filings: 2 available
Open Roles: 14 active jobs
Therapeutic Area Focus
Cardiovascular
5 pipeline
Nephrology
1 pipeline
Marketed
Pipeline

Financials (FY2025)

R&D Spend
$169M140%
Net Income
-$178M
Cash
$114M

Hiring Trend

Stable
14
Open Roles
+1
Added
-1
Filled/Removed

Based on last 4 crawl cycles